Advertisement

Mucositis: Prevention and Management

  • R. Anoop
Chapter

Abstract

Mucositis is defined as inflammation of mucosa as a result of damage to the mucosal lining. Oral erythema, ulceration, and pain are the chief characteristics. It is one of the commonest side effects of radiotherapy (RT) and/or chemotherapy (CT) and is also seen in patients receiving bone marrow transplantation. The severity and duration may vary from patient to patient and may depend on the type and dose of cancer therapeutic agents used [1].

Supplementary material

Video 29.1

Patient with stage 1 V carcinoma of the supraglottis on chemoradiotherapy, 5th week showing grade III mucositis (confluent ulcerations or pseudomembranes; bleeding with minor trauma, severe pain; interfering with oral intake; note the feeding tube) (MP4 56272 kb)

References

  1. 1.
    Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.CrossRefGoogle Scholar
  2. 2.
    Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253–62.CrossRefGoogle Scholar
  3. 3.
    Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manag. 2009;36:522–32.CrossRefGoogle Scholar
  4. 4.
    Nonzee NJ, Dandade NA, Markossian T, et al. Evaluating the supportive care costs of severe radio-chemotherapy-induced mucositis and pharyngitis. Cancer. 2009;113:1446–52.CrossRefGoogle Scholar
  5. 5.
    Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation and impact on quality of life. Cancer. 2008;113:2704–13.CrossRefGoogle Scholar
  6. 6.
    Sonis ST. The pathobiology of mucositis. Semin Oncol Nurs. 2004;20:11–5.CrossRefGoogle Scholar
  7. 7.
    Anthony L, Bowen J, Garden A, Hewson I, Sonis S. New thoughts on the pathobiology of regiment-related mucosal injury. Support Care Cancer. 2006;14:516–8.CrossRefGoogle Scholar
  8. 8.
    Scully C, Epstein JB, Sonis ST. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003;25:1057–70.CrossRefGoogle Scholar
  9. 9.
    Pignon J-P, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112–4.CrossRefGoogle Scholar
  10. 10.
    Rosenthal DI, Mendoza TR, Chambers, et al. The MD Anderson symptom inventory–head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008;72:1355–61.CrossRefGoogle Scholar
  11. 11.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefGoogle Scholar
  12. 12.
    Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.CrossRefGoogle Scholar
  13. 13.
    US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009.Google Scholar
  14. 14.
  15. 15.
    Cleeland CS. Symptom burden: multiple symptoms and their impact on patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16–21.CrossRefGoogle Scholar
  16. 16.
    Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91–100.CrossRefGoogle Scholar
  17. 17.
    De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol. 2016;100:147–66.CrossRefGoogle Scholar
  18. 18.
    Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–43.CrossRefGoogle Scholar
  19. 19.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRefGoogle Scholar
  20. 20.
    Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46:452–6.CrossRefGoogle Scholar
  21. 21.
    Scully C, Epstein JB, Sonis ST. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck. 2004;26:77–84.CrossRefGoogle Scholar
  22. 22.
    Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009;19:29–34.CrossRefGoogle Scholar
  23. 23.
    Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;1:2.Google Scholar
  24. 24.
    Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Cancer Netw. 2008;6:S1–21.CrossRefGoogle Scholar
  25. 25.
    Nagarajan K. Chemo-radiotherapy induced oral mucositis during IMRT for head and neck cancer-an assessment. Med Oral Patol Oral Cir Bucal. 2015;20:e273.CrossRefGoogle Scholar
  26. 26.
    Rosenthal DI, Chambers MS, Fuller CD, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;72:747–55.CrossRefGoogle Scholar
  27. 27.
    Kruser TJ, Rice SR, Cleary KP, et al. Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. Technol Cancer Res Treat. 2013;12:383–9.CrossRefGoogle Scholar
  28. 28.
    Sanguineti G, Endres EJ, Gunn BG, Parker B. Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer? Int J Radiat Oncol Biol Phys. 2006;66:931–8.CrossRefGoogle Scholar
  29. 29.
    Stokman MA, Spijkervet FK, Burlage FR, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind, randomised clinical trial. Br J Cancer. 2003;88:1012–6.CrossRefGoogle Scholar
  30. 30.
    McGuire DB, Correa ME, Johnson J, et al. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14:541–7.CrossRefGoogle Scholar
  31. 31.
    Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.CrossRefGoogle Scholar
  32. 32.
    Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–45.CrossRefGoogle Scholar
  33. 33.
    Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.CrossRefGoogle Scholar
  34. 34.
    Peterson DE, Öhrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21:327–32.CrossRefGoogle Scholar
  35. 35.
    Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.CrossRefGoogle Scholar
  36. 36.
    Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29:2808–14.CrossRefGoogle Scholar
  37. 37.
    Moshkovska T, Mayberry J. It is time to test low level laser therapy in great Britain. Postgrad Med J. 2005;81:436–41.CrossRefGoogle Scholar
  38. 38.
    Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of he-ne laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:180–6.CrossRefGoogle Scholar
  39. 39.
    de Lima AG, Villar RC, de Castro G, et al. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2012;82:270–5.CrossRefGoogle Scholar
  40. 40.
    Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II—clinical perspectives and management. J Dent Res. 2007;86:506–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • R. Anoop
    • 1
  1. 1.Department of Radiation OncologyAmrita Institute of Medical Sciences, Amrita Vishwa VidyapeethamKochiIndia

Personalised recommendations